Effect of Autogenic Relaxation Therapy on Caregivers on Perceived Stress Quality of Life and Caregiver Burden

Effect of Autogenic Relaxation Therapy on Caregivers on Perceived Stress Quality of Life and Caregiver Burden: a Randomized Controlled Study

Caregivers are also faced with multiple stress factors. Autogenic relaxation therapy will help caregivers relax and take time for themselves by getting away from the stressful life they have lived. Although there are various studies on this subject (Chegeni et al. 2018, Seo and Kim 2019, Ramiraz-Garcia et al. 2020, Wang et al. 2021, Bagheri et all 2021, Ozhanlı and Akyuz 2022), there is no study on caregivers as far as we could reach. As a result of this study, nurses will help caregivers, whom they work one-on-one in most areas, to relax, thus helping to increase the quality of patient care in home environments and contributing to the increase in the quality of life of the caregiver. Thus, caregivers will be able to manage care more actively and effectively both at home and in clinics.

Based on this purpose, the aim of the study is to reduce the anxiety level of caregivers, increase the quality of life and reduce the burden of care after autogenic relaxation therapy to be applied to caregivers.

Study Overview

• Status: Active, not recruiting
• Conditions: Caregiver; Caregiver Burnout; Care Burden
• Intervention / Treatment: Behavioral: relaxin; Other: kontrol

• Study Type: Interventional
• Enrollment (Estimated): 64
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Turkey
  • Konya, Turkey, 42450
    • Necmettin Erbakan Üniversitesi

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Being over 18 years old
• Being able to answer data collection forms
• Being able to speak Turkish
• Being able to provide continuous or partial care to a patient for at least 3 months
• Being able to communicate

Exclusion Criteria:

• Having epilepsy
• Not speaking or understanding Turkish
• Having a neurological disability
• Having had an acute myocardial infarction
• Being diagnosed with schizophrenia and major depression
• Being addicted to alcohol or drugs
• Having a history of loss of consciousness

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: control	Other: kontrol; no intervention
Experimental: intervention	Behavioral: relaxin; caregivers relaxing and care burden

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Principial	A decrease in the perceived stress scale score indicates a decrease in stress, an increase in the quality of life scale score indicates an increase in the quality of life, and a decrease in the care burden scale score indicates a decrease in the care burden. The secondary outcome measure is the decrease in the Perceived Stress Scale score, the increase in the Quality of Life Scale Score, and the decrease in the care burden scale score after autogenic relaxation therapy applied to caregivers.	1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
second	The secondary outcome measure is that caregivers feel better after autogenic relaxation therapy, are able to perform autogenic relaxation therapy on their own, and are least affected by the disadvantages of the care burden.	3 month

Collaborators and Investigators

• Sponsor: Seda KARAKAYA ERGUN

Study record dates

Study Major Dates

• Study Start (Actual): November 7, 2024
• Primary Completion (Estimated): November 30, 2024
• Study Completion (Estimated): February 20, 2025

Study Registration Dates

• First Submitted: November 7, 2024
• First Submitted That Met QC Criteria: November 12, 2024
• First Posted (Estimated): November 13, 2024

Study Record Updates

• Last Update Posted (Estimated): November 13, 2024
• Last Update Submitted That Met QC Criteria: November 12, 2024
• Last Verified: June 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavioral Symptoms; Stress, Psychological; Caregiver Burden; Physiological Effects of Drugs; Peripheral Nervous System Agents; Neuromuscular Agents; Muscle Relaxants, Central; Methocarbamol
• Other Study ID Numbers: 2023/369

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No